<!DOCTYPE html><html><head><link rel="stylesheet" href="../displacy.css"></head><body><section class="edgaug_item7" id="edgaug_item7_id">Item 7.</a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"><a href="#a_011">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: center"><a href="#a_011">26</a></td><td style="font-size: 10pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left; padding-left: 0.125in"><a href="#a_012">Item 7A.</a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"><a href="#a_012">Quantitative and Qualitative Disclosures about Market Risk</a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: center"><a href="#a_012">37</a></td><td style="font-size: 10pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-size: 10pt; text-align: left; padding-left: 0.125in"><a href="#a_013">Item 8.</a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"><a href="#a_013">Financial Statements and Supplementary <mark data-entity="product">Data</mark></a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: center"><a href="#a_013">38</a></td><td style="font-size: 10pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left; padding-left: 0.125in"><a href="#g_001">Item 9.</a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"><a href="#g_001">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: center"><a href="#g_001">66</a></td><td style="font-size: 10pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-size: 10pt; text-align: left; padding-left: 0.125in"><a href="#g_002">Item 9A.</a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"><a href="#g_002">Controls and Procedures</a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: center"><a href="#g_002">66</a></td><td style="font-size: 10pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left; padding-left: 0.125in"><a href="#g_003">Item <mark data-entity="cardinal">9B.</mark></a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"><a href="#g_003">Other Information</a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: center"><a href="#g_003">67</a></td><td style="font-size: 10pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-size: 10pt; font-weight: bold; text-align: left"><a href="#g_004">PART <mark data-entity="org">III</mark></a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left; padding-left: 0.125in"><a href="#g_005">Item 10.</a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"><a href="#g_005">Directors, Executive Officers and Corporate Governance</a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: center"><a href="#g_005">67</a></td><td style="font-size: 10pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-size: 10pt; text-align: left; padding-left: 0.125in"><a href="#g_006">Item 11.</a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"><a href="#g_006">Executive Compensation</a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: center"><a href="#g_006">68</a></td><td style="font-size: 10pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left; padding-left: 0.125in"><a href="#g_007">Item 12.</a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"><a href="#g_007">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: center"><a href="#g_007">69</a></td><td style="font-size: 10pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-size: 10pt; text-align: left; padding-left: 0.125in"><a href="#g_008">Item 13.</a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"><a href="#g_008">Certain Relationships and Related Transactions, and Director Independence</a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: center"><a href="#g_008">69</a></td><td style="font-size: 10pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left; padding-left: 0.125in"><a href="#g_009">Item 14.</a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"><a href="#g_009">Principal Accounting Fees and Services</a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: center"><a href="#g_009">69</a></td><td style="font-size: 10pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-size: 10pt; font-weight: bold; text-align: left"><a href="#g_010">PART IV</a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left; padding-left: 0.125in"><a href="#g_011">Item 15.</a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"><a href="#g_011">Exhibits,  Financial Statement Schedules</a></td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: center"><a href="#g_011">69</a></td><td style="font-size: 10pt; text-align: left"> </td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><font style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> </font></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><a name="a_001"></a><b>PART I</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>This Report may
contain "forward-looking statements," within the meaning of <mark data-entity="law">Section 27A</mark> of <mark data-entity="law">the Securities Act</mark> of <mark data-entity="date">1933</mark>, as amended, and/or
Section 21E of <mark data-entity="law">the Securities Exchange Act</mark> of <mark data-entity="date">1934</mark>, as amended. Those statements may include, but are not limited to, discussions
regarding our intent, belief or current expectations with respect to (i) our strategic plans; (ii) trends in the demand for our
products and services; (iii) trends in the industries that consume our products and services; (iv) our ability to develop new products
and services; (v) our ability to make capital expenditures and finance operations; (vi) global economic conditions, especially
as they impact our markets; (vii) our cash position; (<mark data-entity="person">viii</mark>) our ability to integrate a new sales team; (ix) our ability to service
our outstanding indebtedness and (x) our expectations regarding the volume of new bookings, pricing, gross profit margins and liquidity.
Investors in our common shares are cautioned that reliance on any forward-looking statement involves risks and uncertainties, including
the risk factors beginning on page 16 of this Report. Although we believe that the assumptions on which the forward-looking statements
contained herein are based are reasonable, any of those assumptions could prove inaccurate and, as a result, the forward-looking
statements based upon those assumptions could be significantly different from actual results. In light of the uncertainties inherent
in any forward-looking statement, the inclusion of a forward-looking statement herein should not be regarded as a representation
by us that our plans and objectives will be achieved. We do not undertake any obligation to update any forward-looking statement,
except as required by law. The following amounts are in <mark data-entity="cardinal">thousands</mark> unless otherwise indicated.</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><a name="a_002"></a><b><i><section class="edgaug_item1" id="edgaug_item1_id">ITEM 1 – BUSINESS</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Bioanalytical Systems,
Inc. and its subsidiaries (“We,” “Our,” “us,” the “Company,” or “BASi”)
is a contract research organization ("<mark data-entity="work_of_art">CRO</mark>") that provides drug discovery and development services to the pharmaceutical,
chemical, and medical device industries, and sells analytical instruments to the pharmaceutical development and contract research
industries. Our mission is to provide product developers with superior scientific research and innovative analytical instrumentation
in order to bring revolutionary new products to market quickly and safely. Our strategy is to provide services that will generate
high-quality and timely data in support of new product approval or expand their use. Our clients and partners include pharmaceutical,
biotechnology, biomedical device, academic and government organizations. We provide innovative technologies and products and a
commitment to quality to help clients and partners accelerate the development of safe and effective products and maximize the returns
on their research and development investments. We offer an efficient, variable-cost alternative to our clients’ internal
product development programs. Outsourcing development work to reduce overhead and speed product approvals through the <mark data-entity="org">Food and
Drug Administration</mark> ("FDA") and other regulatory authorities is an established alternative to in-house product development
efforts. We derive our revenues from sales of our research services and instruments, both of which are focused on evaluating product
safety and efficacy. The Company has been involved in the research of products to treat diseases in numerous therapeutic areas
for <mark data-entity="date">over 45 years</mark> since its formation as a corporation organized in Indiana in <mark data-entity="date">1974</mark>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We support both the
non-clinical and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, but also
including biotherapeutics and devices. Our scientists have the skills in analytical instrumentation development, chemistry, computer
software development, histology, pathology, physiology, medicine, surgery, analytical chemistry, drug metabolism, pharmacokinetics,
and toxicology to make the services and products we provide increasingly valuable to our current and potential clients. Our principal
clients are scientists engaged in analytical chemistry, drug safety evaluation, clinical trials, drug metabolism studies, pharmacokinetics
and basic research from small start-up biotechnology companies to many of the largest global pharmaceutical companies. We are committed
to bringing scientific expertise, quality and speed to every drug discovery and development program to help our clients develop
safe and effective life-changing therapies.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Developments
within the industries we serve have a direct, and sometimes material, impact on our operations. Currently, many large
pharmaceutical companies have major "blockbuster" drugs that are nearing the end of their patent protections. This
puts significant pressure on these companies both to develop new drugs with large market opportunity, and to re-evaluate
their cost structures and the time-to-market of their products. Contract research organizations have benefited from these
developments, as the pharmaceutical industry has turned to out-sourcing to both reduce fixed costs and to increase the speed
of research and data development necessary for new product applications. The number of significant drugs that have reached or
are nearing the end of their patent protection has also benefited the generic drug industry. Generic drug companies provide a
significant source of new business for CROs as they develop, test and manufacture their generic compounds.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<!-- Field: Page; Sequence: 3; Value: 2 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><font style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> </font></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A significant portion
of innovation in the pharmaceutical industry is now being driven by smaller, venture capital funded drug discovery companies. Many
of these companies are "single-molecule" entities, whose success depends on <mark data-entity="cardinal">one</mark> innovative compound. While several biotech
companies have reached the status of major pharmaceutical companies, the industry is still characterized by smaller entities. These
developmental companies generally do not have the resources to perform much of the research within their organizations, and are
therefore dependent on the <mark data-entity="person">CRO</mark> industry for both their research and for guidance in preparing their regulatory submissions. These
companies have provided significant new opportunities for the <mark data-entity="person">CRO</mark> industry, including <mark data-entity="person">BASI</mark>. We believe that the Company is ideally
positioned to serve these clients as they look for alternatives to the large CROs that cater primarily to the large pharmaceutical
company segment of the marketplace.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Industry Overview </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Drug discovery and
development is the process of creating drugs for the treatment of human and animal disease. The drug discovery process aims to
identify potential drug candidates, while the drug development process involves the testing of these drug candidates in animals
and humans to meet requirements for regulatory approval. The process for researching and developing new medicines is growing in
difficulty and length. On average, it takes <mark data-entity="date">at least ten years</mark> for a new medicine to complete the journey from initial discovery
to the marketplace, with clinical trials alone taking <mark data-entity="date">six to seven years</mark> on average. The average cost to research and develop each
successful drug is estimated to be <mark data-entity="money">$2.6 billion</mark>. This number incorporates the cost of failures – of the <mark data-entity="cardinal">thousands</mark> and sometimes
<mark data-entity="cardinal">millions</mark> of compounds that may be screened and assessed early in the R&amp;D process, only a few will ultimately receive approval.
The overall probability of clinical success (the likelihood that a drug entering clinical testing will eventually be approved)
is estimated to be <mark data-entity="percent">less than 10%</mark>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The drug development
services industry provides independent product development services to pharmaceutical companies, biotechnology companies, and
government organizations. This industry has evolved from providing limited clinical trial services in <mark data-entity="date">the 1970s</mark> to a full-service
industry <mark data-entity="date">today</mark> characterized by broader relationships with clients and by service offerings that encompass the entire drug development
process, including non-clinical efficacy and safety evaluations, study design, clinical trial management, data collection, biostatistical
analyses, regulatory consulting, clinical laboratory and diagnostic services, pre- and post-approval safety analysis, product
registration and post-approval support.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Over <mark data-entity="date">the past few decades</mark>,
technological advances, as well as the emergence of the biotechnology industry, have dramatically changed the drug discovery process.
New and improved technologies have evolved such as ultra-high-throughput screening, new in vitro and in vivo preclinical profiling
techniques and the gene-based drug research commonly referred to as genomics. The objective of these innovations is to find more
drug targets and to screen chemical compounds against targets much more quickly, with literally
<mark data-entity="cardinal">millions</mark> of compounds possible.
This process is expected to produce many more molecules having the ability to affect biological activity. These molecules then
need to be tested quickly and economically to determine their viability as potentially safe and effective drug candidates.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Trends Affecting the Drug Discovery
and Development Industry</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our services and products
are primarily marketed globally to pharmaceutical, medical research and biotechnology companies and institutions (academic and
governmental) engaged in drug research and development. The research services industry is highly fragmented among many niche vendors
as well as a small number of consolidating larger companies; the latter offer an ever-growing portfolio of start-to-finish pharmaceutical
development services. Our services and products may have distinctly different clients (including separate divisions in a single
large pharmaceutical company) and requirements. We believe that market trends in the pharmaceutical and biotech industries demonstrate
an increasing emphasis towards outsourcing, as companies seek to maintain reduced internal resources in favor of variable cost
models that offer high quality and higher accountability alternatives to meet their drug discovery, development and manufacturing
needs. We believe that our clients are facing increased pressure to outsource facets of their research and development activities
and that the following factors will increase client outsourcing.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<!-- Field: Page; Sequence: 4; Value: 2 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><font style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> </font></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><u>Accelerated Drug Development</u></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clients continue to
demand faster, more efficient, more selective development of an increasing pool of drug and device candidates. Consequently, our
clients require fast, high-quality service in order to make well-informed decisions to quickly exclude poor candidates and speed
development of successful ones. The need for additional development capacity to exploit more opportunities, accelerate development,
extend market exclusivity and increase profitability drives the demand for outsourced services.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><u>Increase in Potential New Drug Candidates</u></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While research and
development spending and the number of drug candidates are increasing, the time and cost required to develop a new drug or device
candidate have also increased. Many small and virtual pharmaceutical and biotechnology companies do not have sufficient internal
resources to pursue development of all of the new drug and device candidates on their own. Consequently, these companies are looking
to the drug discovery and development services industry for cost-effective, innovative and rapid means of developing new drugs.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><u>Cost Pressures of Introducing New
Drugs</u></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Market forces, healthcare
reform and other governmental initiatives place significant pressures on pharmaceutical and biotechnology companies to reduce drug
prices. In addition, increased competition as a result of patent expiration, market acceptance of generic drugs, and governmental
and privately managed care organization efforts to reduce healthcare costs have added to drug pricing pressures. The pharmaceutical
industry is responding by consolidating, streamlining operations, decentralizing internal discovery and development processes,
and minimizing fixed costs. In addition, increased pressures to differentiate products and justify drug pricing are resulting in
an increased focus on healthcare economics, safety monitoring and commercialization services. Moreover, pharmaceutical and biotechnology
companies are attempting to increase the speed and efficiency of internal new drug discovery and development processes.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><u>Patent Expiration</u></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As exclusivity ends
with patent expiry, drug companies defend their proprietary positions against generic competition with various patent extension
strategies. Both the drug company pursuing these extensions and the generic competitors provide additional opportunities for <mark data-entity="org">the
Company</mark>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><u>Alliances</u></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Strategic alliances
allow pharmaceutical companies to share research know-how and to develop and market new drugs faster in more diverse, global markets.
We believe that such alliances will lead to a greater number of potential drugs in testing, many under study by small and virtual
companies lacking broad technical resources. These small companies can add shareholder value by further developing new products
through outsourcing, reducing risk for potential allies.  Clients seek realistic business partnerships with their service
provider in an effort to ensure that costs are controlled and scientific continuity is maintained as their development programs
progress. We have long-standing business relationships with many pharmaceutical companies and continue to offer flexible services
and adapt to our clients’ requirements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><u>Mergers and Acquisitions</u></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Consolidation in the
pharmaceutical industry as well as its supporting contract research industry is commonplace. As pharmaceutical industry firms blend
personnel, resources and business activities, we believe they will continue to streamline operations and minimize staffing, which
will lead to more outsourcing and a dependence on small and virtual drug discovery efforts to feed their pipelines. Consolidation
may result in a disruption in the progress of drug development programs as merging companies rationalize their respective drug
development pipelines. In addition, recent consolidation within the contract research industry has created a unique opportunity
for the emergence of mid-market providers who can offer clients a high degree of “touch” not only in study execution,
but in program design and regulatory agency interactions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<!-- Field: Page; Sequence: 5; Value: 2 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><font style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> </font></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><u>Biotechnology Industry and Virtual
Drug Company Growth</u></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The U.S. biotechnology
industry has grown rapidly over <mark data-entity="date">the last decade</mark> and has emerged as a key client segment for the drug discovery and development
services industry. In <mark data-entity="date">recent years</mark>, this industry has generated significant numbers of new drug candidates that will require development
and regulatory approval. Many biotechnology drug developers do not have in-house resources to conduct early stage drug development.
Many new companies choose only to carry a product to a developed stage sufficient to attract a partner who will manufacture and
market the drug. Because of the time and cost involved, these companies rely heavily on CROs to conduct research for their drug
candidates.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><u>Unique Technical Expertise</u></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The increasing complexity
of new drug candidates requires highly specialized, innovative, solution-driven research not available in all client labs. We believe
that this need for unique technical expertise will increasingly lead to outsourcing of research activity. In addition, the reliance
of the pharmaceutical industry on small innovative drug discovery companies which are often overlooked by large CROs creates an
opportunity for strategic partnership with small, consulting-based and innovative CROs such as ours.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><u <mark data-entity="product">Data</mark><Management and Quality Expertise</u></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our clients and worldwide
regulatory authorities require more data, greater access to that data, consistent and auditable management of that data, and greater
security and control of that data. We have made significant investments in software throughout our contract services groups to
optimize efficiency and promote compliance with regulations and market expectations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><u>Globalization of the Marketplace</u></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Foreign firms rely
on independent development companies like ours with experience in the U.S. to provide integrated services through all phases of
product development and to assist in preparing complex regulatory submissions. Domestic drug firms are broadening product availability
globally, demanding local regulatory approval. We believe that we and other domestic service providers with global reach, established
regulatory expertise, and a broad range of integrated development services and products will benefit from this trend.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Solution </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We address the needs
of the pharmaceutical and biotechnology industries, as well as academic, non-profit and government organizations, for drug discovery
and development by providing integrated products and services to help our clients maximize the return on their research and development
investments. Our application of innovative technologies and products and our commitment to quality throughout the drug discovery
and development process offer our clients a way to identify and develop successful drugs and devices more quickly and cost-effectively.
We have obtained significant drug development expertise from <mark data-entity="date">more than 40 years</mark> of operation.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The Company's Role in the Drug Development
Process</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to providing
research support prior to identification of new product candidates, after a new drug candidate is identified and carried through
this preliminary screening, the development process for new drugs has <mark data-entity="cardinal">three</mark> distinct phases.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1)            The
<b><i>nonclinical phase</i></b> includes safety testing to prepare an Investigational New Drug ("<mark data-entity="org">IND</mark>") application for
submission to the FDA. The"<mark data-entity="org">IND</mark>"must be accepted by the FDA before the drug candidate can be initially tested in humans. Once a
pharmacologically active molecule is fully analyzed to confirm its potential utility, the initial dosage form for clinical trials
is created. An analytical chemistry method is developed to enable reliable quantification. Stability and purity of the formulation
are also determined. </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clients work
with our nonclinical services group to establish initial pharmacokinetics (PK), pharmacodynamics (PD) and safety
characteristics of the drug candidate. These safety studies range from dose ranging studies, that involve acute safety
evaluation of drug candidates and medical devices to chronic, multi-year <mark data-entity="org">oncogenicity</mark> and reproductive toxicity studies. Dose
formulation analysis is provided by our pharmaceutical analysis group. <mark data-entity="person">Bioanalyses</mark> of blood sampled under these protocols by
our bioanalytical services group provide pharmacokinetic and metabolism data that is used with the safety and toxicity
information to determine the exposure required to demonstrate toxicity. A no observable adverse effect level is then
established for the drug and sets the basis for future safety testing and clinical phase I studies. Upon successful
completion of nonclinical safety studies, an"<mark data-entity="org">IND</mark>"submission is prepared and reviewed by FDA prior to initiation of human
clinical trials.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<!-- Field: Page; Sequence: 6; Value: 2 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><font style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> </font></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of our products
are designed for use in discovery and nonclinical development. The <i><mark data-entity="product">Culex</mark></i>® family of robotic automated dose delivery,
blood and other <mark data-entity="org">biofluids</mark> sampling and physiological parameters measurement systems enable researchers to quickly and cost effectively
determine <mark data-entity="org">PK/PD</mark> profiles of drugs in large and small animal models. The <i><mark data-entity="product">Culex</mark></i>® system allows experiments on freely moving
conscious animals from early research for therapeutic target validation to lead optimization of compounds. Using the <i><mark data-entity="product">Culex</mark></i>®
system, researchers are able to automatically dose and sample in-vivo to develop pharmacokinetic and pharmacodynamic profiles of
drugs during early screening in rodents and other animals quickly and cost effectively. Our bioanalytical services group utilizes
our depth of expertise in liquid chromatography with detection by mass spectrometry to support research, nonclinical and clinical
programs. We also offer bioanalytical services that utilize electrochemistry, <mark data-entity="person">spectrophotometric</mark> (<mark data-entity="org">UV/Vis</mark> or fluorescence) and <mark data-entity="product">Corona</mark>
Discharge detection as options. We have invested in robotics and mass spectrometry systems. Application of this technology allows
us to rapidly develop and validate methods for new compounds and obtain information suitable for regulatory submission.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2)            The
<b><i>clinical phase</i></b> further explores the safety and efficacy of the drug candidate in humans. The sponsor conducts Phase
I human clinical trials in a limited number of healthy individuals to determine safety and tolerability. Bioanalytical assays determine
the availability and metabolism of the active ingredient following administration. Expertise in method development and validation
is critical, particularly for new chemical entities. During the clinical phase of development, additional non-clinical animal studies
(including sub-chronic and chronic toxicology studies, carcinogenicity studies, reproductive toxicology studies, etc.) are performed
to allow the drug to proceed through clinical development and to support product registration.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Exhaustive safety,
tolerability and dosing regimens are established in patients in Phase II trials. Phase <mark data-entity="org">III</mark><clinical trials verify efficacy and
safety. After successful completion of Phase <mark data-entity="org">III</mark><trials, the sponsor of the new drug submits <mark data-entity="org">a New Drug Application</mark> ("<mark data-entity="org">NDA</mark>")
or Biologics License Application ("<mark data-entity="work_of_art">BLA</mark>") to the FDA requesting that the product be approved for marketing. Early manufacturing
demonstrates production of the substance in accordance with <mark data-entity="org">FDA Good Manufacturing Practices</mark> ("<mark data-entity="work_of_art">GMP</mark>") guidelines. <mark data-entity="product">Data</mark><are compiled in an"<mark data-entity="org">NDA</mark>" or for biotechnology products a"<mark data-entity="work_of_art">BLA</mark>" for submission to the FDA requesting approval to market the drug or
product. The bioanalytical sample count per study grows rapidly from Phase I through Phase <mark data-entity="org">III</mark>< Phase II and <mark data-entity="org">III</mark><studies may take
<mark data-entity="date">several years</mark> to complete, supported by well-proven and consistently applied analytical methods.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our services include
evaluation of bioequivalence and bioavailability to monitor the rate and extent to which a drug is available in the body and to
demonstrate that the availability is consistent between formulations. We also offer in-vitro bioequivalence testing for poorly-absorbed
oral drugs. We offer support and testing services in clinical sample development, release and stability.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3)            The
<b><i>Post-approval phase </i></b>follows FDA approval of the"<mark data-entity="org">NDA</mark>"or"<mark data-entity="work_of_art">BLA</mark>" This includes production and continued analytical and
clinical monitoring of the drug. The post-approval phase also includes development and regulatory approval of product modifications
and line extensions, including improved dosage forms. The drug manufacturer must comply with quality assurance and quality control
requirements throughout production and must continue analytical and stability studies of the drug during commercial production
to continue to validate production processes and confirm product shelf life. Samples from each manufactured batch must be tested
prior to release of the batch for distribution to the public. </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also provide services
during the post-approval phase, including bioequivalence studies of new formulations, line extensions, new disease indications
and drug interaction studies. Our ability to offer <mark data-entity="org">GMP</mark> electrochemical detection services has provided increased business opportunities
for release testing.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Increases in our services
offerings have resulted in our ability to provide a broader range of services to our clients, often using combined services of
several disciplines to address program needs. Our ability to solve problems by combining our knowledge base, services and products
has been a factor in our selection by major pharmaceutical companies to assist in several preclinical through post-approval phases.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<!-- Field: Page; Sequence: 7; Value: 2 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><font style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> </font></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Company Services and Products</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><u>Overview</u></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We focus on developing
innovative services and products that increase efficiency and reduce costs associated with taking new drugs to market. We operate
in two business segments – contract research services and research products, both of which address the bioanalytical, nonclinical,
and clinical research needs of drug and device developers. Both segments arose out of our expertise in a number of core technologies
designed to quantify trace chemicals in complex matrices.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><u>Contract Research Services</u></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The contract research
services segment provides screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory
compliance and quality control testing. Revenues from the contract research services segment were <mark data-entity="money">$39.0 million</mark> for <mark data-entity="date">fiscal 2019</mark>.
The following is a description of the services provided by our contract research services segment:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-size: 10pt"><b><i>Analytical Method Development and Validation</i></b><i>: </i>Analytical
methods, primarily performed in <mark data-entity="gpe">West Lafayette</mark>, Indiana and <mark data-entity="gpe">St. Louis</mark>, Missouri, are developed and validated to ensure that data
generated are accurate, precise, reproducible and reliable and are used consistently throughout the drug development process and
in later product support. Both early-stage, fit-for-purpose discovery methods and fully <mark data-entity="org">GLP</mark>-validated methods are generated to
provide appropriate and timely responses to the client’s situation.</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-size: 10pt"><b><i>Drug Metabolism, <mark data-entity="org">Bioanalysis</mark>, and Pharmacokinetics Testing</i></b><i>:
</i>We analyze samples from in vitro, preclinical and clinical studies to identify and measure drug and metabolite concentrations
in complex biological matrices. Drug metabolism, bioanalysis and pharmacokinetics studies are performed at our facilities in St.
Louis and <mark data-entity="gpe">West Lafayette</mark>, Indiana.</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-size: 10pt"><b><i>Stability Testing</i></b><i>: </i>We test stability of nonclinical
drug dosing formulations and collected bioanalysis samples to ensure the integrity of all solutions used in nonclinical and clinical
studies and post-study analyses. Results from sample shipping and storage studies assist our clients in maintaining sample integrity
throughout the process from collection to analysis.</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><font style="font-size: 10pt"><b><i>In Vivo Pharmacology</i></b><i>: </i>We provide preclinical
<i>in vivo </i>sampling services for the continuous monitoring of chemical changes in life, in particular, how a drug enters, travels
through, and is metabolized in living systems. Those services are performed in customized facilities in <mark data-entity="gpe">St. Louis</mark>,and <mark data-entity="gpe">West Lafayette</mark>,using our robotic <i><mark data-entity="product">Culex</mark></i>® <mark data-entity="product">APS</mark> (Automated Pharmacology System). In addition, we conduct selected focused animal pharmacology
studies evaluating efficacy of new drug candidates at our facility in <mark data-entity="gpe">St. Louis</mark>,</font></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><b><i>Non-clinical <mark data-entity="org">Toxicology and Pathology Services</mark></i></b><i>: </i>We provide safety testing
in studies ranging from acute safety monitoring of drugs and medical devices to chronic, multi-year <mark data-entity="org">oncogenicity</mark> studies in our <mark data-entity="gpe">St. Louis</mark>, <mark data-entity="gpe">Gaithersburg</mark>, and <mark data-entity="gpe">Evansville</mark> sites. At our <mark data-entity="gpe">Gaithersburg</mark>,site, safety evaluation focused on developmental and reproductive
toxicology is also conducted. Our capabilities in toxicologic pathology and evaluation of tissues from animal efficacy models are
located in our <mark data-entity="gpe">St. Louis</mark>,site. Our site in <mark data-entity="facility">Fort Collins</mark> offers surgical modeling and focused evaluation of biomedical devices.</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><b><i>Archiving Services:</i></b> We provide climate-controlled archiving services for our clients’
data and samples at all of our facilities.</td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><u>Research Products</u></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We focus our products
business on expediting preclinical screening of developmental drugs. We compete in small niches of the <mark data-entity="money">multibillion-dollar</mark> analytical
instrument industry. The products business targets unique niches in life science research. We design, develop, manufacture and
market state-of-the-art:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><i>In vivo</i> sampling systems and accessories (including disposables, training and systems qualification)</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify">Physiology monitoring tools</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify">Liquid chromatography and electrochemistry instruments platforms</td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<!-- Field: Page; Sequence: 8; Value: 2 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><font style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> </font></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenues for our products
segment were <mark data-entity="money">$4.6 million</mark> for <mark data-entity="date">fiscal 2019</mark>. We offer two (2) principal product lines: <mark data-entity="org">Analytical Products</mark> and In vivo <mark data-entity="org">Sampling Products</mark>.
The following is a brief description of the products offered:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><b><i <mark data-entity="org">Analytical Products</mark> </i></b> Analytical products consist of our liquid chromatographic and
electrochemical instruments with associated accessories. The critical component of these products is the Epsilon<b><i>® </i></b>electrochemical
platform. This platform incorporates all the hardware capabilities needed for most electrochemical experiments but can be modified
through software development. The market for our analytical products is comprised principally of academic institutions and industrial
research companies.</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><b><i>In vivo <mark data-entity="org">Sampling Products</mark>. </i></b><i>In vivo</i> sampling products consist of the <i><mark data-entity="norp">Culex</mark>®</i>
family of automated <i>in vivo</i> sampling and dosing instruments. These instruments are used by pharmaceutical researchers to
dose animals and collect biological samples (blood, bile, urine, microdialysate, feces or any bio-fluid) from the animals. Since
dosing and sample collections are automated, animals are not manually handled, reducing stress on the animals and producing more
representative pharmacological data. Behavior and other physiological parameters can also be monitored simultaneously. Compared
to manual methods, the <i><mark data-entity="product">Culex</mark></i>® products offer significant reduction in test model use and comparable reduction in labor.
The line also includes <i>in vivo</i> sampling devices sold to drug developers and medical research centers to assist in the study
of a number of medical conditions including stroke, depression, Alzheimer’s and Parkinson’s diseases, diabetes and
osteoporosis.</td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Clients</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have regularly provided
our services and/or products to most of the top 25 pharmaceutical companies in the world, as ranked by the number of research and
development projects. <mark data-entity="percent">Approximately 8.6%</mark> of our revenues were generated from clients outside of <mark data-entity="loc">North America</mark> in <mark data-entity="date">fiscal 2019</mark>.and
2018, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In <mark data-entity="date">fiscal 2019</mark>.our
Services group continued its presence at several important existing clients. In <mark data-entity="date">fiscal 2019</mark>. <mark data-entity="cardinal">one</mark> client accounted for approximately
6.7% of total sales and 8.0% of total trade accounts receivable at <mark data-entity="date">September 30, 2019</mark>. In <mark data-entity="date">fiscal 2018</mark> this client accounted for
approximately 11.2% of total sales and 4% of total trade accounts receivable at <mark data-entity="date">September 30, 2018</mark>. The client discussed is included
in our Services segment. There can be no assurance that our business will move away from dependence upon a limited number of client
relationships.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sales and Marketing</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We promote our services
through concentrated business development efforts, scientist-to-scientist communications and centralized corporate marketing programs
and social media to both large and small pharmaceutical and biotechnology companies, as well as academic and government research
institutions. We recognize that our growth depends upon our ability to continually improve client satisfaction in order to deepen
existing, and create new, client relationships.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our sales and global
marketing initiatives include integrated campaigns designed to help differentiate and promote our products and services. Through
trade events, online and print advertising in trade publications, direct communication, newsletters, social media and our website,
we provide our perspective on current industry challenges and developments to create an ongoing dialogue with our clients and to
promote our industry expertise, quality, technology and innovation. We reinforce key messages and selling points through client
visits, presentations, corporate material and at trade events and industry conferences.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We encourage and sponsor
the participation of our scientific and technical personnel in a variety of professional endeavors, including via speaking engagements,
the presentation of papers at <mark data-entity="org">national and international professional trade meetings</mark> and the publication of scientific articles
in medical and pharmaceutical journals. Through these endeavors we seek to further our reputation for professional excellence.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30,
2019, in addition to our leadership team and scientists, we had 11 employees on our global sales and marketing staff focused on
both our Services and Products business segments. To promote our products, we have a network of 16 established distributors covering
<mark data-entity="gpe">Japan</mark>, <mark data-entity="loc">the Pacific Basin</mark>, <mark data-entity="loc">South America</mark>, <mark data-entity="loc">the Middle East</mark>, India, <mark data-entity="gpe">South Africa</mark> and <mark data-entity="loc">Eastern Europe</mark>. All of our distributor relationships
are managed from our corporate headquarters in <mark data-entity="gpe">West Lafayette</mark>, Indiana.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<!-- Field: Page; Sequence: 9; Value: 2 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><font style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> </font></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Contractual Arrangements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our service contracts
typically establish an estimated fee to be paid for identified services. In most cases, some percentage of the contract costs is
paid in advance. While we are performing a contract, clients often adjust the scope of services to be provided based on interim
project results. Fees are adjusted accordingly. Generally, our fee-for-service contracts are terminable by the client upon written
notice of <mark data-entity="date">30 days</mark> or less for a variety of reasons, including the client's decision to forego a particular study, the failure of
product prototypes to satisfy safety requirements, and unexpected or undesired results of product testing. Cancellation or delay
of ongoing contracts may result in fluctuations in our <mark data-entity="date">quarterly</mark> and annual results. We are generally able to recover, at minimum,
our invested costs when contracts are terminated.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products business
offers both annual and multi-year service and maintenance agreements on many of our product lines.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Competition</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><u>Services</u></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We compete with in-house
research, development, quality control and other support service departments of pharmaceutical and biotechnology companies as well
as other <mark data-entity="org">Contract Research Organizations</mark> ("CROs") that compete in this industry. Several of our competitors have significantly
greater financial resources than we do. The largest <mark data-entity="org">CRO</mark> competitors offering similar research services include:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify">Covance, Inc. now part of <mark data-entity="org">LabCorp</mark>;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify">Pharmaceutical Product Development, Inc.;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify"><mark data-entity="org">Charles River Laboratories, Inc.</mark>; and</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify">Quintiles Transnational Holdings, Inc.</td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CROs generally compete on:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify">regulatory compliance record;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify">reputation for on-time quality performance;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify">quality systems;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify">previous experience;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify">medical and scientific expertise in specific therapeutic areas;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify">scientist-to-scientist relationships;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify">quality of contract research;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify">financial viability;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify">database management;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify">statistical and regulatory services;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify">ability to recruit investigators;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify">ability to integrate information technology with systems to optimize research efficiency;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify">quality of facilities;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify">international presence with strategically located facilities; and</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify">price.</td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><u>Products</u></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Though many global
analytical instruments competitors exist, we have a long-standing network of clients who are repeat buyers and recommend our products.
In contrast, there are few competitors for our <i>in vivo</i> sampling products. The primary market is large pharmaceutical research
departments and academic research institutions. Our differentiators are high quality, flexibility to meet clients’ specific
needs and superior technical support and service. We provide equipment that enables our clients to attain premium scientific laboratory
information on a reasonable operating investment. As clients’ needs constantly change, we continually refine our products
and develop new products which meet our operating objectives.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<!-- Field: Page; Sequence: 10; Value: 2 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><font style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> </font></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Government Regulation</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to various
regulatory requirements designed to ensure the quality and integrity of our data and products. These regulations are promulgated
primarily under <mark data-entity="org">the Federal Food, Drug and Cosmetic Act</mark>, and include <mark data-entity="law">Good Laboratory Practice</mark> ( <mark data-entity="org">GLP</mark>-), <mark data-entity="org">Good Manufacturing
Practice</mark> ("<mark data-entity="work_of_art">GMP</mark>"), Bioequivalence regulations (“<mark data-entity="work_of_art">BE</mark>”) and Good Clinical Practice ("<mark data-entity="org">GCP</mark>") guidelines
administered by the FDA. The standards of <mark data-entity="org">GLP</mark>- <mark data-entity="org">GMP</mark>,“<mark data-entity="work_of_art">BE</mark>”and"<mark data-entity="org">GCP</mark>"are required by the FDA and by similar regulatory authorities around
the world. These requirements demand rigorous attention to employee training; detailed documentation; equipment validation; careful
tracking of changes and routine auditing of compliance. Noncompliance with these standards could result in disqualification of
project data collected by the Company. Material violations of <mark data-entity="org">GLP</mark>- <mark data-entity="org">GMP</mark>,“<mark data-entity="work_of_art">BE</mark>”or"<mark data-entity="org">GCP</mark>"regulations could result in regulatory sanctions
and, in severe cases, could also result in a discontinuance of selected operations.<i> </i> Since our formation, we have been
inspected, on a routine basis, by the FDA. The FDA has inspected our <mark data-entity="gpe">West Lafayette</mark>,location <mark data-entity="cardinal">twenty-two</mark> times and our <mark data-entity="gpe">Evansville</mark> location six times, our <mark data-entity="gpe">St. Louis</mark>, <mark data-entity="org">MO</mark> location <mark data-entity="cardinal">three</mark> times and our <mark data-entity="gpe">Gaithersburg</mark>, <mark data-entity="org">MD</mark> location <mark data-entity="cardinal">three</mark> times. Of the <mark data-entity="cardinal">thirty-four</mark> FDA
inspections, <mark data-entity="cardinal">twenty-two</mark> were without findings.  Where the FDA had findings, which have not been significant to our operations,
we have taken actions to address the findings and the FDA has informed us that it deemed the actions taken as acceptable.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also subject
to, and required to comply with, regulations from <mark data-entity="org">the Environmental Protection Agency</mark> (“<mark data-entity="org">EPA</mark>”). The“<mark data-entity="org">EPA</mark>”has inspected
the <mark data-entity="gpe">West Lafayette</mark>,location twice. Both inspections ended without findings.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not experienced
any significant problems to date in complying with the regulations of the FDA and“<mark data-entity="org">EPA</mark>”and do not believe that any existing or proposed
regulations will require material capital expenditures or changes in our method of operation.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><u><mark data-entity="org">Analytical Services</mark></u></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Laboratories that provide
information included in INDs, NDAs and BLAs must conform to regulatory requirements that are designed to ensure the quality and
integrity of the testing process. Most of our contract research services are subject to government standards for laboratory practices
that are embodied in regulations for <mark data-entity="org">GLP</mark>- <mark data-entity="org">GMP</mark>,“<mark data-entity="work_of_art">BE</mark>”and"<mark data-entity="org">GCP</mark>" The FDA,“<mark data-entity="org">EPA</mark>”and other regulatory authorities require that test results
submitted to such authorities be based on studies conducted in accordance with the regulations listed above. These requirements
include but are not restricted to the following areas:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify">Resources – organization, personnel, facilities and equipment;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify">Rules – protocols and written procedures;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify">Characterization – test items and test systems;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify">Documentation – raw data, final report and archives; and</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">·</font></td><td style="text-align: justify">Quality assurance unit – formalized internal audit function.</td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We must also maintain
reports for each study for specified periods for auditing by the study sponsor and by the FDA or similar regulatory authorities
in other parts of the world. Noncompliance with these regulations can result in the disqualification of data collected during the
preclinical trial.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i> </i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><u>Nonclinical Services</u></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our animal research
facilities are subject to a variety of federal and state laws and regulations, including <mark data-entity="law">The Animal Welfare Act</mark> and the rules and
regulations enforced by <mark data-entity="org">the United States Department of Agriculture</mark> ("<mark data-entity="law">USDA</mark>") and <mark data-entity="org">the National Institutes of Health</mark> ("<mark data-entity="org">NIH</mark>").
These regulations establish the standards for the humane treatment, care and handling of animals by dealers and research facilities.
Our animal research facilities maintain detailed standard operating procedures and other documentation necessary to comply with
applicable regulations for the humane treatment of the animals in our custody. In addition to being licensed by the <mark data-entity="org">USDA</mark> as a research
facility, we are also accredited by <mark data-entity="org">the Association for Assessment and Accreditation of Laboratory Animal Care International</mark> and
have registered assurance with the"<mark data-entity="org">NIH</mark>"</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<!-- Field: Page; Sequence: 11; Value: 2 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><font style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> </font></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><u><mark data-entity="org">Quality Assurance and Information</mark>
Technology</u></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To ensure compliance
with applicable regulations, we have established quality assurance programs at our facilities, which include auditing of test data,
personnel training, review of procedures and regular inspection of facilities. Regulatory guidelines serve as a basis for our Standard
Operating Procedures (“SOPs”) where applicable. On an ongoing basis, we endeavor to standardize SOPs across all relevant
operations. We have both developed and purchased software to ensure compliant documentation, handling and reporting of laboratory-generated
study data.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We adhere to 21 <mark data-entity="org">CFR</mark>
Part 11 (FDA regulations on electronic records and electronic signatures that define the criteria under which electronic records
and electronic signatures are considered to be trustworthy, reliable and equivalent to paper records).  Our contract research
operations were compliant with applicable <mark data-entity="org">U.S. FDA</mark> regulations (including 21 <mark data-entity="org">CFR</mark>
Part 11) in our analytical, bioanalytical, toxicology,
laboratory information management, and document management systems.  Systems compliant with 21 <mark data-entity="org">CFR</mark>
Part 11 were formally validated
and released for use in regulated studies.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We manage our business
systems through the use of an Enterprise Resource Planning ("<mark data-entity="work_of_art">ERP</mark>") system. We are continually refining and adjusting
our <mark data-entity="org">ERP</mark> system to improve efficiency, provide better management tools and address changes in our business. These changes are appropriately
documented and tested before implementation. We also test these systems in connection with management’s annual review of
our internal control systems. Management’s assessment and report on disclosure controls and procedures and internal controls
over financial reporting is included in Item 9A.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><u>Controlled, Hazardous, and Environmentally
Threatening Substances</u></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of our development
and testing activities are subject to <mark data-entity="law">the Controlled Substances Act</mark> administered by <mark data-entity="org">the Drug Enforcement Agency</mark> ("<mark data-entity="org">DEA</mark>"),
which strictly regulates all narcotic and habit-forming substances. We maintain restricted-access facilities and heightened control
procedures for projects involving such substances due to the level of security and other controls required by the"<mark data-entity="org">DEA</mark>" In addition,
we are subject to other federal and state regulations concerning such matters as occupational safety and health and protection
of the environment.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our laboratories are
subject to licensing and regulation under federal, state and local laws relating to hazard communication and employee right-to-know
regulations, the handling and disposal of medical specimens and hazardous waste, as well as the safety and health of laboratory
employees. All of our laboratories are subject to applicable federal and state laws and regulations relating to the storage and
disposal of laboratory specimens, including regulations of <mark data-entity="org">the Environmental Protection Agency</mark>  <mark data-entity="org">the Department of Transportation</mark>,
<mark data-entity="org">the National Fire Protection Agency</mark> and <mark data-entity="org">the Resource Conservation and Recovery Act</mark>. Although we believe that we are currently in
compliance in all material respects with such federal, state and local laws, failure to comply could subject us to denial of the
right to conduct business, fines, criminal penalties and other enforcement actions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The regulations of
<mark data-entity="org">the U.S. Department of Transportation</mark>, <mark data-entity="org">the U.S. Public Health Service</mark> and <mark data-entity="org">the U.S. Postal Service</mark> apply to the surface and air
transportation of laboratory specimens. Our laboratories also comply with <mark data-entity="org">the International Air Transport Association</mark> regulations
which govern international shipments of laboratory specimens. Furthermore, when materials are sent to a foreign country, the transportation
of such materials becomes subject to the laws, rules and regulations of such foreign country.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><u>Safety</u></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to comprehensive
regulation of safety in the workplace, <mark data-entity="org">the Occupational Safety and Health Administration</mark> has established extensive requirements
relating to workplace safety for health care employers whose workers may be exposed to blood-borne pathogens such as HIV and the
hepatitis B virus. These regulations, among other things, require work practice controls, protective clothing and equipment, training,
medical follow-up, vaccinations and other measures designed to minimize exposure to chemicals, and transmission of blood-borne
and airborne pathogens. Relevant employees receive initial and periodic training focusing on compliance with applicable hazardous
materials regulations and health and safety guidelines.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<!-- Field: Page; Sequence: 12; Value: 2 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><font style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> </font></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<!-- Field: Split-Segment; Name: 002 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><u>HIPAA</u></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Health Insurance
Portability and Accountability Act of <mark data-entity="date">1996</mark> ("HIPAA"), <mark data-entity="org">the U.S. Department of Health and Human Services</mark> regulates the
disclosure of confidential medical information in the United States. We have had a global privacy policy in place since <mark data-entity="date">January
2001</mark> and believe that we are in compliance with HIPAA and current <mark data-entity="org">European Union</mark> requirements regarding confidential medical information.
We continue to monitor our compliance with these regulations, and we intend to take appropriate steps to promote compliance as
these and other privacy regulations are revised or additional regulations come into effect.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Product Liability and Insurance</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain product
liability and professional errors and omissions liability insurance, providing coverage on a claims-made basis. Additionally, in
certain circumstances, we seek to manage our liability risk through contractual provisions to be indemnified by the client or covered
by the client’s liability insurance policies. Also, in certain types of engagements, we seek to limit our contractual liability
to clients to the amount of fees received. Our client contractual arrangements are subject to negotiation, and the terms and scope
of indemnification, liability limitation and insurance coverage vary by client and project.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In <mark data-entity="date">fiscal 2019</mark>.and
2018, we spent $627 and $596, respectively, on research and development. Separate from our contract research services business,
we maintain applications research and development to enhance our products business. Expenditures cover hardware and software engineering
costs, laboratory supplies, labor, prototype development and laboratory demonstrations of new products and applications for those
products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our
patents, trademarks, copyrights and other proprietary rights are important to our business. Accordingly, we actively seek protection
for those rights both in the United States and abroad. Where we deem it to be an appropriate course of action, we will vigorously
prosecute patent infringements. The loss of any <mark data-entity="cardinal">one</mark> or more of our patents, trademarks, copyrights or other proprietary rights
could be material to our consolidated revenues or earnings.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently hold four
U.S. federally registered trademarks. We also have two issued U.S. patents on <mark data-entity="product">the Dried Blood Spot</mark> (DBS) sampling card for the
<i><mark data-entity="product">Culex</mark></i>® Automated Blood Sampling Instrumentation<font style="color: #0070C0">. </font>There are also pending international
patent applications for this technology in
<mark data-entity="gpe">Japan</mark>, <mark data-entity="gpe">Canada</mark>, and Europe. Additionally, we have <mark data-entity="cardinal">three</mark> issued U.S. patents for the No
Blood Waste technology for the <i><mark data-entity="person">Culex</mark></i>® instrument. There are <mark data-entity="cardinal">thirteen</mark> issued international patents for this technology
in Europe,
<mark data-entity="gpe">Japan</mark>,and <mark data-entity="gpe">Canada</mark>, There are two additional issued U.S. patents and <mark data-entity="cardinal">fifteen</mark> issued international patents in <mark data-entity="gpe">Germany</mark>,
<mark data-entity="gpe">Denmark</mark>, Europe, <mark data-entity="gpe">Spain</mark>, <mark data-entity="gpe">France</mark>, <mark data-entity="gpe">Great Britain</mark>,
<mark data-entity="gpe">Japan</mark>, <mark data-entity="gpe">Sweden</mark>, and <mark data-entity="gpe">Switzerland</mark> relating to the <mark data-entity="norp">Raturn</mark>® technology which can
be used with the <i><mark data-entity="product">Culex</mark></i>® system; two issued U.S. patents and <mark data-entity="cardinal">one</mark> issued <mark data-entity="norp">Canadian</mark> patent relating to pinch valve technology;
and <mark data-entity="cardinal">thirteen</mark> pending international patent applications in <mark data-entity="gpe">Canada</mark>,
<mark data-entity="gpe">Japan</mark>,and Europe relating to a tube assembly system that could
potentially be used in the <i><mark data-entity="product">Culex</mark></i>® system.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our issued patents
are protected for durations ranging from <mark data-entity="date">October of 2019 to August of 2037</mark>. In addition to these formal intellectual property rights,
we rely on trade secrets, unpatented know-how and continuing applications research which we seek to protect through means of reasonable
business procedures, such as confidentiality agreements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Raw Materials</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no specialized
raw materials that are particularly essential to our business. We have a variety of alternative suppliers for the components in
our products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<!-- Field: Page; Sequence: 13; Value: 2 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><font style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> </font></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employees</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At <mark data-entity="date">September 30, 2019</mark>.
we had 311 full-time employees and 11 part-time employees. All employees enter into confidentiality agreements intended to protect
our proprietary information. We believe that our relations with our employees are good. None of our employees are represented by
a labor union. Our performance depends on our ability to attract and retain qualified professional, scientific and technical staff.
The level of competition among employers for skilled personnel is high. We believe that our employee benefit plans enhance employee
morale, professional commitment and work productivity and provide an incentive for employees to remain with the Company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Executive Officers of the Registrant</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
illustrates information concerning the persons who currently serve as our executive officers. Officers are elected <mark data-entity="date">annually</mark> at
the annual meeting of the board of directors.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 94%; margin-left: 0.5in">
<tr style="vertical-align: bottom">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Name</font></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Age</font></td>
<td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Position</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="width: 37%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt"><mark data-entity="person">Robert
    W. Leasure</mark>, <mark data-entity="person">Jr.</mark></font></td>
<td style="width: 30%; font: 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">60</font></td>
<td style="width: 33%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt">President
    and Chief Executive Officer</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt"><mark data-entity="person">John</mark>
    <mark data-entity="person">E. Sagartz</mark>, <mark data-entity="gpe">DVM</mark>, <mark data-entity="gpe">PhD</mark>, <mark data-entity="org">DACVP</mark></font></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">53</font></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt">Chief Strategy Officer</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt">Jill
    C. Blumhoff</font></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">43</font></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt">Chief Financial Officer,
    Vice President-Finance</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt">William
    Pitchford</font></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">65</font></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt">Chief Human Resources
    Officer</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt">D.
    <mark data-entity="person">Thomas</mark> <mark data-entity="person">Oakley</mark></font></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: center">62</td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt">Chief Operations Officer</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt">Joseph
    Flynn</font></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">54</font></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt">Chief Commercial Officer</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt">Philip
    A. Downing</font></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">49</font></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt">Senior Vice President,
    <mark data-entity="org">Preclinical Services</mark></font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt"> </font></td>
<td style="text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt"> </font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt">Michael
    A. Baim, <mark data-entity="person">Ph.D.</mark></font></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">62</font></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt">Senior Vice President,
    <mark data-entity="org">Analytical Operations</mark></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><mark data-entity="person">Robert
Leasure</mark>, <mark data-entity="person">Jr.</mark><</b>joined the Company as President and Chief Executive Officer on <mark data-entity="date">January 12, 2019</mark>. Mr. Leasure serves as the managing
partner and president of <mark data-entity="org">LS Associates LLC</mark> (“LS”), a management and turnaround firm formed in <mark data-entity="date">2002</mark>. From September
of 2016 until Mr. Leasure’s employment, the Company engaged LS as a financial consultant. Mr. Leasure's experience working
with management teams in areas including strategic planning and implementation, problem solving, operations, mergers and acquisitions
and financial transactions, and in particular Mr. Leasure’s experience leading the Company’s turnaround and current
growth, well situate him for his role as President and Chief Executive Officer and as a director.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><mark data-entity="person">John</mark>
<mark data-entity="person">E. Sagartz</mark>, <mark data-entity="gpe">DVM</mark>, <mark data-entity="gpe">PhD</mark>, <mark data-entity="org">DACVP</mark>< </b>joined the Company as part of the Company’s acquisition of <mark data-entity="org">Seventh Wave Laboratories</mark> on
<mark data-entity="date">July 2, 2018</mark>. <font style="background-color: white">Following the acquisition, Dr. Sagartz joined BASi’s Board of Directors
to help guide operations in order to provide broader solutions and greater scientific expertise to the Company’s clients.
</font>Dr. Sagartz began his career as a toxicologic pathologist at <mark data-entity="org">Searle/Monsanto</mark> in <mark data-entity="date">1996</mark>  and held positions of increasing responsibility
as section head, director, preclinical development site head, and fellow, following Monsanto’s merger with <mark data-entity="org">Pharmacia</mark>. After
<mark data-entity="org">Pfizer</mark>’s acquisition of <mark data-entity="org">Pharmacia</mark>.in <mark data-entity="date">2003</mark>, Dr. Sagartz founded <mark data-entity="org">Seventh Wave Laboratories</mark> where he served as President and
Chief Executive Officer, and Chief Strategy Officer. Dr. Sagartz is an adjunct associate professor of <mark data-entity="org">Comparative Medicine</mark> at <mark data-entity="org">St.
Louis University’s College of Medicine</mark> and serves on <mark data-entity="org">the Board of Directors</mark> of <mark data-entity="org">the Missouri Biotechnology Association</mark>. He
received his Bachelor of Science and Doctor of Veterinary Medicine degrees from <mark data-entity="org">Kansas State University</mark> and, after completing residency
training in anatomic pathology, earned his Doctor of Philosophy from <mark data-entity="org">The Ohio State University</mark>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<!-- Field: Page; Sequence: 14; Value: 2 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><font style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> </font></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><mark data-entity="person">Jill C. Blumhoff</mark>
</b>joined the Company as Assistant Controller on <mark data-entity="date">October 7, 2007</mark> and thereafter was promoted to positions of greater responsibility
in the <mark data-entity="org">Accounting and Finance</mark> area including Director of Financial Reporting and Director of Finance and IT until reaching her
present position of Chief Financial Officer and Vice President of Finance on <mark data-entity="date">May 11, 2016</mark>. She has been responsible for all aspects
of financial reporting and disclosure as well as leading the Company’s efforts in building the financial support structure
at BASi. Ms. Blumhoff held various roles of increasing levels of responsibility in financial reporting and analysis at <mark data-entity="org">Wabash National
Corporation</mark> after beginning her career at Ernst &amp; Young LLP. Ms. Blumhoff received a Bachelor of Science degree in accounting
from <mark data-entity="org">the University of the Illinois at Urbana-Champaign</mark> in <mark data-entity="date">1998</mark>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><mark data-entity="person">William D. Pitchford</mark>
</b>joined the Company as Chief Human Resources Officer on <mark data-entity="date">August 28, 2019</mark>. <font style="background-color: white">Prior to joining
the Company, Mr. Pitchford held senior level positions within the human resources functions at <mark data-entity="org">Ford Motor Company</mark>, <mark data-entity="org">Rio Tinto Alcan
Corporation</mark> and, most recently, at <mark data-entity="org">Wabash National Corporation</mark> as Senior Vice President of Human Resources. Mr. Pitchford received
his undergraduate degree in Criminology &amp; Sociology at <mark data-entity="org">Indiana State University</mark>, and his <mark data-entity="org">Master of Arts in Human Resources
Management</mark> at <mark data-entity="org">Central Michigan University</mark>.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>D. <mark data-entity="person">Thomas</mark> <mark data-entity="person">Oakley</mark></b>
was appointed COO of the Company on <mark data-entity="date">February 11, 2019</mark>, and is responsible for leading its operations among four sites. Mr. <mark data-entity="person">Oakley</mark><joined the Company as part of the Seventh Wave acquisition in 2018, where <mark data-entity="person">Oakley</mark><previously served as CEO. Prior to his tenure
at <mark data-entity="org">Seventh Wave Laboratories</mark>  Mr. <mark data-entity="person">Oakley</mark><led <mark data-entity="org">DTO Associates</mark> and served as President and COO of <mark data-entity="org">MPI Research</mark>, President and CEO
of <mark data-entity="org">ChanTest Corporation</mark>, and President and CEO of <mark data-entity="org">Bridge Laboratories</mark>. He has also held leadership positions with <mark data-entity="org">the Sarah Cannon
Research Institute</mark> and Covance. He served in <mark data-entity="org">the United States Army</mark>, from which he was honorably discharged with the rank of Captain.
Mr. <mark data-entity="person">Oakley</mark><holds an MBA in management, finance and accounting from the <mark data-entity="org">J.L. Kellogg Graduate School of Management</mark> at <mark data-entity="org">Northwestern
University</mark>, and a BA in <mark data-entity="org">Economics</mark> from <mark data-entity="org">Ripon College</mark>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><mark data-entity="person">Joe Flynn</mark></b> joined
the Company in <mark data-entity="date">July 2018</mark> as part of the Seventh Wave acquisition. He was appointed to his current role as the Chief Commercial
Officer in <mark data-entity="date">February 2019</mark>. In this role, Joe is responsible for leading sales and marketing efforts across BASi’s four sites.
Mr. Flynn has an esteemed career as a senior executive in contract research, with over <mark data-entity="date">25 years</mark> of strategic and operational experience
focusing on pharmaceutical research and development. Most recently, he served as Chief Commercial Officer and Executive Vice President
of <mark data-entity="org">Seventh Wave Laboratories</mark>  Prior to his tenure at <mark data-entity="org">Seventh Wave Laboratories</mark>  Mr. Flynn was a global vice president of sales
and client services for multiple divisions of <mark data-entity="org">Covance Laboratories</mark>. Prior to Covance, he held operational roles at <mark data-entity="org">PPD Inc.</mark> and
<mark data-entity="org">ABC Laboratories</mark> (now <mark data-entity="person">Eurofins</mark>). Mr. Flynn began his career with a BS in Biochemistry from <mark data-entity="org">the University of Missouri</mark>, <mark data-entity="gpe">Columbia</mark>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><mark data-entity="org">Philip Downing</mark></b>
has over <mark data-entity="date">22 years</mark> of pharmaceutical experience in drug discovery, toxicology/non-clinical, and clinical research. Traditionally
trained as a bioanalytical chemist, Philip joined the Company as an analytical chemist in <mark data-entity="date">1997</mark>, rapidly moving into leadership
positions such as Director of><mark data-entity="org">Analytical Services</mark>< General Manager, and <mark data-entity="org">Sr</mark>. Director of Preclinical, until reaching his present
position as Vice President of <mark data-entity="org">Preclinical Services</mark>< Prior to BASi, Philip worked at <mark data-entity="org">GFi Pharmaceuticals</mark> (now <mark data-entity="facility">Covance Labs</mark> –
Clinical Division) as an <mark data-entity="org">Analytical Scientist</mark>, and <mark data-entity="org">RSO</mark> designing and validating radiolabeled and non-radiolabeled assays used to
support clinical <mark data-entity="org">ADME</mark> studies. He earned a Bachelor’s Degree in Chemistry and Biology from <mark data-entity="org">Indiana University</mark> and is a member
of <mark data-entity="org">the Society of Toxicology,</mark> <mark data-entity="org">American College of Toxicology</mark> and <mark data-entity="org">the American Chemical Society</mark>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><mark data-entity="person">Michael Baim</mark>, <mark data-entity="person">Ph.D.</mark></b>
joined the Company in <mark data-entity="date">May 2018</mark> as Senior VP of <mark data-entity="org">Analytical Operations</mark>< Dr. Baim is an energetic and passionate leader who brings
to BASi over <mark data-entity="date">thirty years</mark> of experience in the pharmaceutical and lab management industries. He is well-versed in analytical methodology
and project design, and has a proven track record of delivering significant and sustainable profitable growth across many different
business segments. Dr. Baim began his career at The Procter &amp; Gamble Company in <mark data-entity="date">1984</mark>, and has since held several leadership,
management and technical positions at other prominent companies including <mark data-entity="org">Novartis</mark> and <mark data-entity="org">Bristol-Myers Squibb</mark>/Mead Johnson. Most
recently, he served as an analytical laboratory director, designing a new analytical chemistry lab and revitalizing chemistry operations
by adding new technologies and staff to optimize technical guidance and improve customer service. These efforts resulted in a sustained,
double-digit growth rate for the company. Dr. Baim received his BA in chemistry from <mark data-entity="org">Whitman College</mark> in Washington State. He then
studied analytical chemistry as an <mark data-entity="org">American Chemical Society Analytical Research Fellow</mark> at <mark data-entity="org">Washington State University</mark>, where he
earned his <mark data-entity="gpe">PhD</mark>, He is currently working towards his MBA in marketing management.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<!-- Field: Page; Sequence: 15; Value: 2 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><font style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> </font></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Investor Information</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We file various reports
with, or furnish them to, <mark data-entity="org">the Securities and Exchange Commission</mark> (the “<mark data-entity="org">SEC</mark>”), including our annual reports on Form
10-K, <mark data-entity="date">quarterly</mark> reports on Form <mark data-entity="cardinal">10-Q</mark>, current reports on Form 8-K, and amendments to such reports. These reports are available
free of charge upon written request or by visiting www.BASinc.com/invest. Inquiries from shareholders, security analysts, portfolio
managers, registered representatives and other interested parties including media inquiries should be directed to:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">BASi Investor Relations,</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attn: <mark data-entity="person">Jill Blumhoff</mark></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">2701 <mark data-entity="facility">Kent Avenue</mark>, <mark data-entity="gpe">West Lafayette</mark>, IN 47906
USA</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Phone 765-463-4527, Fax 765-497-1102,
ir@basinc.com</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><a name="a_003"></a><b><i></section><div id="item_end"></div><div id="edgaug_item7_end"></div></body></html>